283 results match your criteria Squamous Cell Carcinoma of the Prostate

Association Between Diabetes Risk Reduction Diet and Lung Cancer Risk in 98,159 Participants: Results From a Prospective Study.

Front Oncol 2022 28;12:855101. Epub 2022 Apr 28.

Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.

Purpose: To evaluate the association between diabetes risk reduction diet (DRRD) score and the risk of lung cancer in a large population.

Methods: Data of participants in this study were collected from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated in the Cox proportional hazards regression model for the association of DRRD score and lung cancer incidence in all included participants. Read More

View Article and Full-Text PDF

Expression and prognostic analyses of the significance of STEAP1 and STEAP2 in lung cancer.

World J Surg Oncol 2022 Mar 28;20(1):96. Epub 2022 Mar 28.

Department of Thoracic Surgery, Heze Municipal Hospital, Heze, 274031, Shandong, China.

Purpose: Lung cancer is the leading cause of cancer-related mortality. STEAP1 and STEAP2 are overexpressed in various cancers. The purpose of this study was to evaluate the expression and prognostic value of STEAP1 and STEAP2 in patients with lung cancer. Read More

View Article and Full-Text PDF

The Prognostic Value and Immunological Role of STEAP1 in Pan-Cancer: A Result of Data-Based Analysis.

Oxid Med Cell Longev 2022 11;2022:8297011. Epub 2022 Mar 11.

Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430060, China.

Purpose: This study is aimed at systematically analyzing the expression, function, and prognostic value of six transmembrane epithelial antigen of the prostate 1 (STEAP1) in various cancers.

Methods: The expressions of STEAP1 between normal and tumor tissues were analyzed using TCGA and GTEx. Clinicopathologic data was collected from GEPIA and TCGA. Read More

View Article and Full-Text PDF

Left supraclavicular (Virchow's) node metastasis detected before primary infradiaphragmatic tumor: a case series.

J Med Case Rep 2022 Jan 26;16(1):33. Epub 2022 Jan 26.

Division of Diagnostic Radiology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.

Background: Metastasis of infradiaphragmatic tumors to the left supraclavicular lymph node is reported to be rare. When metastasis is detected in the left supraclavicular node in patients with head and neck carcinoma, locating the primary cancer remains a difficult and time-consuming challenge despite the dramatic development of screening technologies and treatment methods.

Case Presentation: We report three cases of malignant infradiaphragmatic tumor diagnosed following an initial finding of left supraclavicular node metastasis after surgery for tongue squamous cell carcinoma (follow-up period, range 18-62 months). Read More

View Article and Full-Text PDF
January 2022

Diagnostic and Therapeutic Challenges in a Patient with Synchronous Very High-Risk Prostate Adenocarcinoma and Anal Carcinoma.

Curr Oncol 2022 01 15;29(1):377-382. Epub 2022 Jan 15.

Veterans Affairs New York Harbor Healthcare System, State University of New York-Downstate Medical Center, New York, NY 11209, USA.

A 79-year-old HIV-negative Caucasian man with a medical history of smoking 20 pack-years (quit 40 years prior), early-stage non-small cell lung cancer status post-lobectomy 13 years earlier at an outside hospital without evidence of recurrence, and benign prostatic hypertrophy was diagnosed with synchronous very high-risk prostate adenocarcinoma and early-stage anal basaloid squamous cell carcinoma. He proceeded to undergo concurrent treatment for these tumors, consisting of androgen deprivation therapy, external beam radiation therapy, and a brachytherapy boost for the prostate adenocarcinoma; for the anal carcinoma, he was treated with definitive chemoradiation. Over 3. Read More

View Article and Full-Text PDF
January 2022

[Incidental prostate cancer: A clinicopathological study].

Zhonghua Nan Ke Xue 2021 Feb;27(2):145-149

Department of Urology, Drum Tower Hospital Affiliated to Nanjing University School of Medicine, Nanjing, Jiangsu 210008, China.

Objective: To investigate the clinicopathological characteristics and prognosis of incidental prostate cancer (PCa).

Methods: We retrospectively analyzed the clinical data and pathological characteristics of 96 cases of incidental PCa in 580 patients undergoing radical cystectomy and followed them up for prognosis.

Results: The incidence rate of incidental PCa was 16. Read More

View Article and Full-Text PDF
February 2021

Successful treatment with DCF chemotherapy and radiotherapy for primary squamous cell carcinoma of the prostate.

IJU Case Rep 2021 Nov 23;4(6):421-424. Epub 2021 Aug 23.

Department of Urology Kochi Medical School Kochi Japan.

Introduction: Primary squamous cell carcinoma of the prostate is an extremely rare tumor with poor prognosis. Squamous cell carcinoma of the prostate is estimated to comprise less than 1% of all prostate carcinomas. We report herein a case with clinical response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy with radiotherapy, in a patient with metastatic squamous cell carcinoma of the prostate. Read More

View Article and Full-Text PDF
November 2021

Management of Urological Malignancy in Heart and Lung Transplant Recipients: An Irish National Cohort Study.

Exp Clin Transplant 2021 10;19(10):1069-1075

>From the Department of Urology, Mater Misericordiae University Hospital, Dublin, Ireland.

Objectives: Following the first hearttransplantin Ireland in 1985, there have been almost 700 deceased donor heart and lung transplants carried out in Ireland at a single institution. In this retrospective study, our aim was to assess the incidence and management of urological malignancies arising in this national cohort.

Materials And Methods: Our retrospective analysis included all heart and lung transplant recipients identified as having a urological malignancy. Read More

View Article and Full-Text PDF
October 2021

Genetic Variants of and Are Associated With Risk of Non-Small Cell Lung Cancer.

Front Oncol 2021 15;11:709829. Epub 2021 Sep 15.

Department of Radiology, Duke University Medical Center, Durham, NC, United States.

Background: Single nucleotide polymorphisms (SNPs) are often associated with distinct phenotypes in cancer. The present study investigated associations of cancer risk and outcomes with SNPs discovered by whole exome sequencing of normal lung tissue DNA of 15 non-small cell lung cancer (NSCLC) patients, 10 early stage and 5 advanced stage.

Methods: DNA extracted from normal lung tissue of the 15 NSCLC patients was subjected to whole genome amplification and sequencing and analyzed for the occurrence of SNPs. Read More

View Article and Full-Text PDF
September 2021

Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications.

Virchows Arch 2022 Feb 24;480(2):433-447. Epub 2021 Sep 24.

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.

Cytokeratins (CKs) 5 and 6 are functionally unrelated but often analyzed together using bispecific antibodies in diagnostic immunohistochemistry. To better understand the diagnostic utility of CK5 or CK6 alone, tissue microarrays with > 15,000 samples from 120 different tumor types as well as 608 samples of 76 different normal tissues were analyzed by immunohistochemistry. In normal tissues, both CKs occurred in the squamous epithelium; CK5 dominated in basal and CK6 in suprabasal layers. Read More

View Article and Full-Text PDF
February 2022

Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report.

BMC Med Genomics 2021 09 3;14(1):217. Epub 2021 Sep 3.

Department of Urology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.

Background: Adenosquamous carcinoma of the prostate (ASCP) is an extremely rare and aggressive prostate cancer variant, whose genomic characteristics have not been elucidated. Although liquid biopsy of circulating tumor cells (CTCs) is an emerging topic in oncology, no study has assessed CTCs in patients with ASCP.

Case Presentation: A 76-year-old man presented with discomfort in his urethra. Read More

View Article and Full-Text PDF
September 2021

Squamous cell carcinoma of the prostate with lower urinary tract symptoms: A case report.

Urol Case Rep 2021 Nov 4;39:101796. Epub 2021 Aug 4.

Department of Urology, Hunan Provincial People's Hospital(The First Affiliated Hospital of Hunan Normal University), China.

Primary squamous cell carcinoma of the prostate is a rare tumor. An 80-year-old man was admitted to hospital for half a year because of progressive dysuria and pain. Laboratory examination: TPSA 7. Read More

View Article and Full-Text PDF
November 2021

Patterns of Care and Treatment Outcomes in Locoregional Squamous Cell Carcinoma of the Prostate.

Eur Urol Open Sci 2021 Jan 3;23:30-33. Epub 2021 Jan 3.

Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah, Salt Lake City, Utah.

Primary squamous cell carcinoma is a rare, aggressive disease with historically poor outcomes and no established treatment guidelines. Case reports are limited but describe multiple treatment approaches. Seeking to identify practice patterns and treatment outcomes, we used the US National Cancer Data Base to identify 66 males with locoregional primary squamous cell carcinoma of the prostate treated with surgery, chemotherapy, and/or radiotherapy between 2004 and 2015. Read More

View Article and Full-Text PDF
January 2021

Challenge and Outcome for the Prostate Squamous Cell Carcinoma Which Developed 8 Years after Low-Dose-Rate Brachytherapy Approached by a Combined Multimodal Treatment with High-Dose-Rate Interstitial Brachytherapy, External Beam Radiation Therapy, and Chemotherapy.

Case Rep Oncol 2021 May-Aug;14(2):854-860. Epub 2021 Jun 11.

Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Prostate squamous cell carcinoma (pSCC) rarely develops as a secondary cancer after treatment with low-dose-rate brachytherapy (LDR-BT). There is no established effective treatment for the disease condition. Herein, we present a 78-year-old man who developed pSCC 8 years after LDR-BT. Read More

View Article and Full-Text PDF

Histologic Findings in Surgical Pathology Specimens From Individuals Taking Feminizing Hormone Therapy for the Purpose of Gender Transition.

Arch Pathol Lab Med 2022 01;146(2):252-261

the Department of Laboratory Medicine, University of Washington, Seattle (Greene).

Context.—: Transgender women experience health disparities in all areas of medicine. Within surgical pathology, knowledge gaps relating to the concepts of transgender care exist. Read More

View Article and Full-Text PDF
January 2022

Squamous cell carcinoma of the prostate with concomitant hypercalcemia and normal serum prostate-specific antigen levels.

Pol Arch Intern Med 2021 04 24;131(4):379-380. Epub 2021 Feb 24.

Department of Internal Medicine and Oncological Chemotherapy, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.

View Article and Full-Text PDF

Prostate squamous cell carcinoma developing 11 years after external radiotherapy for prostate adenocarcinoma.

IJU Case Rep 2020 Jul 20;3(4):121-124. Epub 2020 Apr 20.

Department of Urology Kyoto Prefectural University of Medicine Kyoto Japan.

Introduction: Secondary bladder, colon, and rectal cancers are relatively common after prostate radiotherapy. However, secondary squamous cell carcinoma of the prostate is rare.

Case Presentation: An 85-year-old man presented with dysuria and low-serum prostate-specific antigen levels. Read More

View Article and Full-Text PDF

An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer.

EMBO Mol Med 2021 02 29;13(2):e11902. Epub 2020 Dec 29.

Department of Immunology, Institute for Cell Biology, Eberhard Karls University Tuebingen, German Cancer Consortium (DKTK), Partner Site Tuebingen, Tuebingen, Germany.

The prostate-specific membrane antigen (PSMA) has been demonstrated in numerous studies to be expressed specifically on prostate carcinoma cells and on the neovasculature of several other cancer entities. However, the simultaneous expression of PSMA on both, tumor cells as well as tumor vessels remains unclear, even if such "dual" expression would constitute an important asset to facilitate sufficient influx of effector cells to a given tumor site. We report here on the generation of a PSMA antibody, termed 10B3, which exerts superior dual reactivity on sections of prostate carcinoma and squamous cell carcinoma of the lung. Read More

View Article and Full-Text PDF
February 2021

Uncommon Cervical Lesions: A Review and Discussion of the Differential Diagnosis.

Arch Pathol Lab Med 2021 07;145(7):891-902

From the Department of Pathology, University of Michigan Medical School, Ann Arbor.

Context.—: While the vast majority of cervical tumors consist of human papillomavirus (HPV)-related squamous cell carcinoma or adenocarcinoma, a subset of rare tumor types, frequently unrelated to HPV, does occur in this location. These tumors vary widely in prognostic and therapeutic implications, and accurate recognition is crucial to providing appropriate treatment. Read More

View Article and Full-Text PDF

Secondary tumors of the bladder: A survival outcome study.

Ann Diagn Pathol 2020 Oct 14;48:151593. Epub 2020 Aug 14.

University of Texas, MD Anderson Cancer Center, Houston, TX, USA.

The urinary bladder may be involved by a variety of secondary tumors that originate from other organs. Bladder secondary tumors are rare and may be mistaken as bladder primary tumors because of their overlapping morphologic features. To avoid the diagnostic pitfalls, we analyzed the clinicopathologic features of bladder secondary tumors in a large cohort of patients. Read More

View Article and Full-Text PDF
October 2020

Incidental Detection of Elastofibroma Dorsi With 68Ga-FAPI-46 and 18F-FDG PET/CT in a Patient With Esophageal Cancer.

Clin Nucl Med 2021 Feb;46(2):e86-e87

From the Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology.

Abstract: A 71-year-old man underwent 18F-FDG and 68Ga-FAPI-46 PET/CT for initial staging prior to surgery of a squamous cell carcinoma of the lower esophagus under the prospective study NCT04147494. Both scans showed increased uptake in the mid and distal esophagus without evidence of metastatic disease. A soft tissue right infrascapular mass with mild 18F-FDG and moderate 68Ga-FAPI-46 uptake was incidentally found. Read More

View Article and Full-Text PDF
February 2021

Novel genetic variants in genes of the Fc gamma receptor-mediated phagocytosis pathway predict non-small cell lung cancer survival.

Transl Lung Cancer Res 2020 Jun;9(3):575-586

Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA.

Background: Both antibody-dependent cellular cytotoxicity and phagocytosis activate innate immunity, and the Fc gamma receptor (FCGR)-mediated phagocytosis is an integral part of the process. We assessed associations between single-nucleotide polymorphisms (SNPs) in FCGR-related genes and survival of patients with non-small cell lung cancer (NSCLC).

Methods: We evaluated associations between 24,734 (SNPs) in 97 FCGR-related genes and survival of 1,185 patients with NSCLC using a published genome-wide association study (GWAS) dataset from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and validated the results in another independent dataset of 894 NSCLC patients. Read More

View Article and Full-Text PDF

Newly developed primary malignancies in long-term survivors who underwent curative esophagectomy for squamous cell carcinoma of the esophagus.

Surg Today 2021 Jan 7;51(1):153-158. Epub 2020 Jul 7.

Department of Gastroenterological Surgery (Surgery II), Nagoya University Graduate School of Medicine, Nagoya, Japan.

Purpose: We evaluated the efficacy of the long-term follow-up of patients who underwent radical esophagectomy for esophageal squamous cell carcinoma (ESCC) to screen for recurrence and new primary malignancies.

Methods: We retrospectively collected 448 ESCC patients who underwent radical esophagectomy. Esophagogastroduodenoscopy, computed tomography, a stool test and the assessment of the serum concentration of squamous cell carcinoma antigen and carcinoembryonic antigen were performed annually, even over 5 years after esophagectomy. Read More

View Article and Full-Text PDF
January 2021

Metastatic squamous cell carcinoma transformed from prostatic adenocarcinoma following androgen deprivation therapy: A case report with clinicopathologic and molecular findings.

Diagn Cytopathol 2020 Dec 6;48(12):E14-E17. Epub 2020 Jul 6.

VA Palo Alto Health Care System, Pathology and Laboratory Service, Palo Alto, California, USA.

Squamous cell carcinoma (SCC) of the prostate is a rare and clinically aggressive entity that may arise de novo or through transformation of prostatic adenocarcinoma, typically following hormonal or radiation therapy. Confirmation of prostatic origin, especially when evaluating a metastatic focus, often requires correlation with clinical and imaging findings, as the morphologic and immunohistochemical features of SCC are not organ-specific. Comprehensive genomic profiling (CGP) may provide additional information useful for confirming the primary site and for identifying potential targeted therapy options. Read More

View Article and Full-Text PDF
December 2020

European Association of Urology Guidelines on Primary Urethral Carcinoma-2020 Update.

Eur Urol Oncol 2020 08 27;3(4):424-432. Epub 2020 Jun 27.

Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.

Context: Primary urethral carcinoma (PUC) is a rare cancer accounting for <1% of all genitourinary malignancies.

Objective: To provide updated practical recommendations for the diagnosis and management of PUC.

Evidence Acquisition: A systematic search interrogating Ovid (Medline), EMBASE, and the Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews was performed. Read More

View Article and Full-Text PDF

Increased Prostate-Specific Membrane Antigen Uptake in Neurofibromatosis.

Clin Nucl Med 2020 Jun;45(6):465-467

From the Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University/Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou.

A 51-year-old man with 30-year neurofibromatosis and 2-month elevated prostate-specific antigen and back pain underwent a Ga-prostate-specific membrane antigen (PSMA) PET/CT scan for possible prostate cancer. Prostate-specific membrane antigen PET/CT imaging showed no abnormal uptake of the prostate. However, in addition to PSMA uptake in his left lung, thorax, and right ilium, which was confirmed being a lung squamous cell carcinoma by a lung biopsy, widespread uptake was also observed in his skin fibroma lesions. Read More

View Article and Full-Text PDF

Demonstration of microRNA using hybridisation on formalin fixed paraffin wax samples using conventional oligonucleotide probes: a comparison with the use of locked nucleic acid probes.

Br J Biomed Sci 2020 Jul 29;77(3):135-141. Epub 2020 Apr 29.

Life Sciences, University of Westminster , London, UK.

Background: MicroRNAs (miRNAs) regulate the translation of mRNA during gene expression and investigations have highlighted their importance in pathophysiology. qRT-PCR is currently the gold standard method for detecting changes in miRNA expression. However, when used on heterogeneous samples, it cannot identify individual cell types harbouring miRNAs. Read More

View Article and Full-Text PDF

PCAT1: An oncogenic lncRNA in diverse cancers and a putative therapeutic target.

Exp Mol Pathol 2020 06 24;114:104429. Epub 2020 Mar 24.

Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address:

The critical roles of long non-coding RNAs (lncRNAs) in the regulation of diverse biological functions has potentiated them as cancer biomarkers. Among these transcripts is the prostate cancer associated transcript 1 (PCAT1) which has been initially shown to exert oncogenic roles in prostate cancer. Further studies revealed its similar roles in various kinds of human malignancies including both solid tumors and hematological malignancies. Read More

View Article and Full-Text PDF

Post-Brachytherapy Transformation of Prostatic Adenocarcinoma to Squamous Cell Carcinoma: A Cadaver Anatomy Case Report.

Cureus 2019 Nov 18;11(11):e6184. Epub 2019 Nov 18.

Pathology, University of Central Florida College of Medicine, Orlando, USA.

Prostatic squamous cell carcinoma comprises less than 1% of reported prostate cancers. This form of cancer has a poor prognosis with a low survival time following diagnosis and no definitive form of treatment. A Caucasian male cadaver presented with primary pure squamous cell carcinoma of the prostate with metastasis to the liver and local invasion of the bladder, ureter, and rectum. Read More

View Article and Full-Text PDF
November 2019

Transformation of a prostatic adenocarcinoma into squamous cell carcinoma after luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy treatment.

Pan Afr Med J 2019 1;34:125. Epub 2019 Nov 1.

Université de Tunis El Manar, Faculté de Médecine de Tunis, 1007, Tunis, Tunisie.

Squamous cell carcinoma of the prostate is rare and represents 0.5% to 1% of prostatic carcinomas. Transformation of prostatic adenocarcinoma into squamous cell carcinoma after LH-RH agonist intake has been reported in only 8 cases in the literature. Read More

View Article and Full-Text PDF